Salivary Soluble CD44: A Molecular Marker for HNSCC

唾液可溶性 CD44：HNSCC 的分子标记

• 批准号: 6783728
• 负责人: Elizabeth J Franzmann
• 金额: $ 7.58万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-03-01 至 2006-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6783728
• 关键词: CD44 molecule; biomarker; clinical research; diagnosis design /evaluation; enzyme linked immunosorbent assay; head /neck neoplasm; human subject; neoplasm /cancer diagnosis; patient oriented research; rapid diagnosis; saliva; squamous cell carcinoma

DESCRIPTION (provided by applicant): Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 500,000 incident cancers worldwide. The treatment of HNSCC, combinations of surgery, radiation and chemotherapy, often result in significant morbidity and substantial healthcare costs. Elimination of the initial tumor offers the best chance of cure, yet we succeed only 50 percent of the time. Therapy fails most often due to recurrence at the primary site or in the neck, and less often from distant metastases. When initial or recurrent tumors are identified early, treatment outcome is better. Unfortunately the majority of HNSCC are identified in later stage. A marker for HNSCC that is able to detect new cancers and recurrences in early stages would be useful. CD44 may be a molecular marker of malignancy in other tissues and is detectable in body fluids in soluble form (solCD44). Our preliminary data suggest that solCD44 is increased in the saliva of HNSCC tumor patients compared to controls. In this study we will examine the expression of solCD44 in both newly diagnosed HNSCC patients and controls and in HNSCC patients with recurrence or second primaries. We will use a solCD44 ELISA test and a protein assay to evaluate the expression of solCD44 in HNSCC patient's saliva (aim 1). We will compare these to sol CD44 levels in controls that are matched for age, sex, race, socioeconomic status, tobacco and alcohol use. We will use the same assays to evaluate the expression of solCD44 in patients with recurrent or second primary HNSCC matching for previous treatment, original stage, tobacco and alcohol use (aim 2). The results of these studies will determine the validity of soICD44 ELISA test as a screening test for HNSCC.

描述（由申请人提供）： 头颈鳞状细胞癌 (HNSCC) 约占全球癌症发病率 500,000 例。头颈部鳞癌的治疗结合手术、放疗和化疗，通常会导致严重的发病率和巨额的医疗费用。消除最初的肿瘤提供了最好的治愈机会，但成功率只有 50%。治疗失败最常见的原因是原发部位或颈部复发，较少见的是远处转移。如果及早发现初始或复发性肿瘤，治疗效果会更好。不幸的是，大多数 HNSCC 是在后期才被发现的。能够在早期阶段检测新癌症和复发的 HNSCC 标记物将很有用。 CD44 可能是其他组织中恶性肿瘤的分子标志物，并且可以在体液中以可溶形式检测到（solCD44）。我们的初步数据表明，与对照组相比，HNSCC 肿瘤患者唾液中的 solCD44 有所增加。在本研究中，我们将检查新诊断的 HNSCC 患者和对照以及复发或第二次原发的 HNSCC 患者中 solCD44 的表达。我们将使用 solCD44 ELISA 测试和蛋白质测定来评估 HNSCC 患者唾液中 solCD44 的表达（目标 1）。我们将这些与年龄、性别、种族、社会经济地位、烟草和酒精使用相匹配的对照中的 sol CD44 水平进行比较。我们将使用相同的测定法来评估复发性或第二原发性 HNSCC 患者中 solCD44 的表达，这些患者与既往治疗、原始分期、吸烟和饮酒相匹配（目标 2）。这些研究的结果将确定 soICD44 ELISA 测试作为 HNSCC 筛查测试的有效性。